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Abstract
Epidemiological and experimental evidences strongly support the role of estrogens in breast tumor development. Both
estrogen receptor (ER)-dependent and ER-independent mechanisms are implicated in estrogen-induced breast
carcinogenesis. Tamoxifen, a selective estrogen receptor modulator is widely used as chemoprotectant in human breast
cancer. It binds to ERs and interferes with normal binding of estrogen to ERs. In the present study, we examined the effect of
long-term tamoxifen treatment in the prevention of estrogen-induced breast cancer. Female ACI rats were treated with 17b-
estradiol (E2), tamoxifen or with a combination of E2 and tamoxifen for eight months. Tissue levels of oxidative stress
markers 8-iso-Prostane F2a (8-isoPGF2a), superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase, and oxidative
DNA damage marker 8-hydroxydeoxyguanosine (8-OHdG) were quantified in the mammary tissues of all the treatment
groups and compared with age-matched controls. Levels of tamoxifen metabolizing enzymes cytochrome P450s as well as
estrogen responsive genes were also quantified. At necropsy, breast tumors were detected in 44% of rats co-treated with
tamoxifen+E2. No tumors were detected in the sham or tamoxifen only treatment groups whereas in the E2 only treatment
group, the tumor incidence was 82%. Co-treatment with tamoxifen decreased GPx and catalase levels; did not completely
inhibit E2-mediated oxidative DNA damage and estrogen-responsive genes monoamine oxygenase B1 (MaoB1) and cell
death inducing DFF45 like effector C (Cidec) but differentially affected the levels of tamoxifen metabolizing enzymes. In
summary, our studies suggest that although tamoxifen treatment inhibits estrogen-induced breast tumor development and
increases the latency of tumor development, it does not completely abrogate breast tumor development in a rat model of
estrogen-induced breast cancer. The inability of tamoxifen to completely inhibit E2-induced breast carcinogenesis may be
because of increased estrogen-mediated oxidant burden.
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Introduction
Sex hormones have been implicated in the development of
breast cancer [1,2,3]. However, the exact mechanisms underlying
the initiation and progression of estrogen-related cancers remain
elusive. Breast tumor induction is suggested to depend on both the
estrogen receptor (ER)-dependent pathway of estrogen-induced
cell growth and ER-independent pathway that involves estrogen
metabolism and oxidative stress resulting from the redox cycling
of estrogen metabolites [1,4,5,6]. Published literature and our
recent studies strongly support the role of estrogen metabolism-
mediated oxidative stress in estrogen-induced breast carcinogen-
esis [1,2,7,8,9].
Tamoxifen (Tam) is a cancer chemotherapeutic agent of a drug
family known as ER modulators and is widely used as an
anticancer and chemopreventive drug for breast cancer [10,11].
The molecular mechanism(s) underlying the tissue-specificity of
Tam action is not clear. The antagonist effects of Tam in breast
tissue are thought to result from its ability of competing with
estradiol to bind to the ligand-binding domain of the ER and by
inducing conformational changes that block the interaction of ER
with coactivator proteins [12]. Tamoxifen is known to induce a
significant improvement in the overall survival rate from breast
cancer [13]. However, about one-third of ER and progesterone
receptor (PR) positive breast tumors treated with Tam do not
respond to initial treatment, and the remaining 70% are still at risk
to relapse in the future [14]. An increased incidence of
endometrial cancer in breast cancer patients and induction or
promotion of tumorigenesis in human and rat liver treated with
Tam has also been reported [15,16]. The development of
endocrine resistance is a pervasive clinical problem [17,18]. A
number of mechanisms have been proposed to control antiestro-
gen resistance in ER-positive breast cancer, but many details of
these mechanisms continue to be unclear [19]. Moreover, Tam
itself has been shown to possess pro-carcinogenic properties and
strong genotoxic activity both in vivo and in vitro [20]. Tamoxifen
appears to require metabolic activation to exert tumorigenic and
genotoxic activity [21]. A number of earlier studies have shown
that Tam is converted to the genotoxic epoxide, as well as 4- and
2-hydroxy metabolites via enzymatic activation either by liver
cytochrome P450 monoxidase [22] or by different peroxidases
[23,24]. These metabolites can bind to biologically active
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inducing irreversible damage to these molecules [25]. Overall, the
mechanisms of action of Tam depend upon several interlinked
factors and are not well understood. It has previously been
reported that Tam treatment for 6 months abrogates E2-induced
breast cancer [26]. In the present study, we report that long-term
(8 months) Tam treatment does not completely prevent E2-
induced breast cancer in ACI rat breast cancer model, an accepted
animal model of hormonal breast cancer. The lack of complete
inhibition of E2-induced breast cancer by Tam may be because of
the inability of Tam to prevent E2-mediated oxidant stress as is
suggested by the current studies.
Results
Tamoxifen decreases breast tumor incidence and
increases the latency of estrogen-induced mammary
tumor development
Female ACI rats were treated with E2, Tam or Tam + E2 for 8
months. Control animals were sham-operated and received
cholesterol pellet only which was used as a binder for the
preparation of E2 pellets. Mammary tumor incidence in rats co-
treated with E2 and Tam at necropsy was 44% (Table 1). No
palpable tumors were observed in this group till the end of the
treatment time. In contrast, in E2-treated group, the first palpable
breast tumors appeared after 128 days of treatment and mammary
tumor incidence was 82% after 8 months of E2 exposure [7].
Kaplan-Meier survival curve analysis suggests that average tumor
latency was significantly longer for animals in the Tam + E2 group
versus those in E2 group (Figure 1). Co-treatment with Tam and
E2 was associated with a decrease in tumor multiplicity compared
to E2 group (Table 1). In the Tam + E2 group, 1.460.3 tumor
nodules per tumor-bearing animal were observed while in the E2
treatment group, an average of 3.160.7 tumor nodules were
present in tumor-bearing rats (Table 1). No tumors were observed
in sham-operated controls or in Tam-only treated groups. No
morphologic changes were detected in the mammary tissue of
Tam-treated ACI rats relative to those of sham controls (Figure 2).
Mammary tissues from all the animals in the Tam-treated group
displayed normal lobular architecture, consisting of ducts
surrounded by small lobules and were similar to that of controls
and did not exhibit increased proliferation (Figure 2). Analysis of
mammary tissue from all the rats in the Tam + E2 experimental
group revealed less lobular and intraductal proliferation compared
to rats treated with E2 (Figure 2). However, both ductal carcinoma
in situ (DCIS) and micro-invasive cancers were present in the
mammary tissue of animals from E2 and Tam + E2 group
(Figure 2). The mammary tumors from Tam + E2 group have
characteristics similar to E2-induced breast tumors [26,27,28]. No
significant morphological differences were observed between
ovary, kidney, uterus, lung or liver tissues from rats in the Tam
and Tam + E2 groups (data not shown).
Tamoxifen decreases estrogen and progesterone
receptor expression, and E2-induced mammary
proliferation
Estrogen receptor-a and PR expression was analyzed by
immunohistochemical and real-time PCR, respectively. Increased
ER-a protein expression was observed in E2-treated mammary
tissue than the control mammary tissue by immunohistochemical
analysis (Figure 3). In contrast, ER-a protein expression was lower
in Tam and Tam + E2-treated mammary tissues compared to
control mammary tissues (Figure 3). Progesterone receptor mRNA
expression was 9-fold upregulated in E2-treated mammary
compared to the control mammary (Figure 4). Fold changes in
PR mRNA expression were not significantly different in Tam and
Tam + E2-treated mammary tissues compared to control
mammary tissues (Figure 4). Immunohistochemical analysis for
proliferating cell nuclear antigen (PCNA) as a marker for
proliferating cells (26) showed no significant change in PCNA
protein levels between control and Tam-exposed mammary tissues
(Figure 5). PCNA expression in Tam + E2-treated mammary
tissue was more than the Tam alone group but lower than E2-
exposed mammary tissues (Figure 5).
Tamoxifen does not prevent E2-induced oxidative stress
Oxidative stress in the mammary tissue of ACI rats was
evaluated by quantification of 8-isoPGF2a as well as by analysis of
antioxidant enzymes SOD, catalase (CAT) and GPx. 8-iso-
Prostane F2a levels were significantly greater (,5-fold) in the
Tam + E2 group compared to the Tam control group (Figure 6).
In rats treated with E2 only, a similar 5-fold increase in 8-
isoPGF2a levels was observed relative to age-matched cholesterol-
treated controls. The fold increase in 8-isoPGF2a levels was same
in both Tam + E2- and E2-only treated groups (Figure 6). No
significant differences in 8-isoPGF2a levels in liver were detected
between control animals and those treated with E2 or Tam + E2
(data not shown).
Protein expression levels of SODs (SOD1 and SOD2), CAT
and GPx in the mammary tissues were evaluated by western blot
analysis. There were no significant differences observed in protein
expressions levels of SOD1 in Tam-, Tam + E2- and E2-treated
mammary tissues compared to control mammary tissues (Figure 7).
However, SOD2 protein expression was significantly increased in
Tam-, Tam + E2- and E2-treated mammary tissues compared to
control mammary tissues (Figure 7). Highest expression of SOD2
was observed in E2-treated mammary tissues (Figure 7). There was
Table 1. Effects of E2 and Tam treatments on mammary tumor development in female ACI rats.
Treatment Groups n Tumor Incidence (%) Tumor Multiplicity Appearance of First Tumor (day)
Control 10 0 0 NA
E2 11 82* 3.160.7* 128*
Tam 18 0 0 NA
Tam + E2 18 44
# 1.460.3
# At necropsy
Column 1 lists different treatments each group of animals received. The number of animals per group (n) is listed in column 2. Percent tumor incidence after 240 days of
treatment period is listed in column 3, and the average number of tumors per tumor-bearing animal (tumor multiplicity) is listed in column 4. Column 5 lists the day on
which the first tumor appeared in each group (appearance of first tumor). ‘*’ indicates significant difference (p,0.05) compared to control group. ‘#’ indicates
significant difference (p,0.05) between Tam + E2 and control or Tam-treated group.
doi:10.1371/journal.pone.0025125.t001
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treated mammary but it was significantly decreased in Tam- and
Tam + E2-treated mammary tissues in comparison to control
mammary tissues (Figure 7). Catalase expression was significantly
decreased in the mammary tissues of all the groups (E2, Tam,
Tam + E2) compared to control mammary tissues (Figure 7).
The activities of antioxidant enzymes SOD1, SOD2, CAT and
GPx were also quantified in the mammary tissue of rats treated
with E2 or Tam + E2 as well as in their respective control groups.
Approximately, 3- and 14-fold significant upregulation in SOD1
and SOD2 enzyme activities, respectively were detected in E2-
treated mammary tissues compared to control group (Table 2).
Tam- and Tam + E2-treated mammary tissues did not show
significant change in SOD1 and SOD2 activities compared to
controls (Table 2). However, GPx enzyme activities were
significantly downregulated in Tam- and Tam + E2-treated
mammary tissues (,2.3 and ,1.7 fold, respectively) relative to
controls (Table 2). No alterations in CAT activity were detected in
mammary tissues from any experimental group (Table 2). There
was no significant difference in total SOD, CAT and GPx activity
in liver tissues between E2 and their control group as well as
between Tam + E2 and Tam group (data not shown).
Tamoxifen differentially affects Tam-metabolizing
enzymes in ACI rat mammary tissues
Cytochrome P450 (CYP) 3A4, CYP2D6 and flavin containing
monooxygenase 1 (FMO1) are major Tam-metabolizing enzymes
in the body (Figure 8A). Western blotting techniques were
employed to evaluate protein levels of CYP3A4, CYP2D6 and
FMO1 in mammary tissues of E2-, Tam- and Tam + E2-treated
groups and compared to control group (Figure 8B). No significant
changes in CYP3A4 and CYP2D6 protein levels were detected in
mammary tissues of rats from all the experimental groups relative
to controls (Figure 8B). However, western blot analysis of
mammary tissues of rats from E2, and Tam + E2 groups showed
a marked decrease in FMO1 protein expression levels relative to
mammary tissues from control animals (Figure 8B). There was no
significant change observed in FMO1 protein expression levels
between age-matched control and Tam-treated mammary tissues
(Figure 8B).
Tamoxifen does not prevent inhibition of estrogen
responsive genes MaoB1 and Cidec
Tamoxifen prevented expression of classical E2 responsive
genes like ER-a and PR but did not prevent E2-medaited
inhibition of novel E2 responsive genes MaoB1 and Cidec
(Figure 9). Both MaoB1 and Cidec mRNA expression levels were
significantly downregulated in E2-induced mammary tumors, E2-,
and Tam + E2-treated mammary tissues compared to control
mammary tissues (Figure 9). However, expression of these genes
was unchanged in Tam-treated mammary tissues in comparison to
control mammary tissues (Figure 9).
Tamoxifen does not completely prevent estrogen-
induced oxidative DNA damage
Formation of 8-OHdG is a marker of oxidative DNA damage.
An ELISA method was used to detect 8-OHdG as a marker of
oxidative DNA damage in mammary tissues and mammary
tumors. Approximately 1.8- and 3-fold increase (p,0.05) in 8-
OHdG levels was observed in E2-treated mammary and in
Figure 1. Tamoxifen exposure increases the latency of E2-induced breast tumors. Female ACI rats were treated with E2, Tam or Tam + E2
as described in the Materials and Methods section. Kaplan-Meier survival curves for tumor occurrence were plotted for each treatment group, and the
log rank test was used to detect differences in tumor latency curves between groups. Average tumor latency was significantly longer for animals in
the Tam + E2 group versus those in the E2 group. Animals in the control or Tam groups did not develop any tumors and are represented by the same
line on the graph.
doi:10.1371/journal.pone.0025125.g001
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(Figure 10). No difference in 8-OHdG levels between control and
Tam-treated mammary tissues were observed, suggesting that
Tam alone treatment did not induce oxidative DNA damage
(Figure 10). However, 8-OHdG levels were significantly increased
in Tam + E2-treated mammary tissues relative to control and
Tam-only treated mammary tissues (Figure 10).
Discussion
In present study, we have demonstrated that Tam treatment did
not completely abrogate E2-induced mammary tumors in female
ACI rats. Female ACI rat model is an established animal model of
hormonal carcinogenesis [7,8,9,26,29,30,31]. It shares many
features of human breast cancer such as genomic instability,
increased oxidant stress, DNA damage etc. [26,27,28,32,33,34].
In an earlier report, Tam has been shown to completely abrogate
E2-induced breast cancer in the same ACI rat model [26]. This
difference may be because of the increased treatment time in our
studies (8 months) compared to the earlier published study (6
months). The difference in the outcome could not possibly be due
to the lack of Tam supplementation after 6 months because we
recovered remaining part of the Tam tablet after 8 months of
exposure. Furthermore, Tam did not inhibit E2-induced oxidant
stress. However, Tam co-treatment with E2 increased tumor
latency and decreased tumor incidence in ACI rat breast (Figure 1).
We also demonstrated that Tam inhibited E2-mediated prolifer-
ation of mammary tissue (Figure 2). Moreover, low expression
levels of PCNA in Tam-treated mammary tissues further confirm
the histopathological observations of inhibition of E2-induced
proliferation of breast cancer by Tam (Figure 5).
Tamoxifen is a well known selective estrogen receptor
modulator (SERM) that inhibits estrogen signaling by competing
with estrogen in binding to ERs [12]. The classical pathway of
Figure 2. Histopathology of mammary tumor and mammary tissues. Female ACI rats were treated with E2, Tam or Tam + E2 for 240 days as
described in the Materials and Methods section. a) The mammary tissue of a representative control ACI rat shows normal lobular architecture (L) with
branched ducts (D) and normal distribution of fat tissue/adipocytes (A); b) E2-treated mammary tissue shows increased proliferation with dilated
ducts containing inspissated secretions (D) and increased proliferation and expansion of terminal lobular units (HLU) accompanied by compression of
and expansion into the surrounding fat tissue/adipocytes (A); c) Mammary tissue from a rat treated with E2 shows ductal carcinoma in situ (DCIS)
containing inspissated secretions in ducts (D) and micro-invasive cancer (IC); d) The mammary gland of Tam only treated rat shows normal lobular
architecture (L) with branched ducts (D) and normal distribution of fat tissue (A); e) Mammary tissue from Tam + E2-exposed rat displays increased
proliferation compared to control mammary tissue but less than E2-treated mammary tissue. It also shows dilated ducts containing inspissated
secretions (D) and increased proliferation and expansion of terminal lobular units (HLU) accompanied by compression of and expansion into the
surrounding fat tissue (A); f) Mammary tissue from an animal treated with Tam + E2 shows ductal carcinoma in situ (DCIS) containing inspissated
secretions in ducts (D) and micro-invasive cancer (IC). 1006magnification.
doi:10.1371/journal.pone.0025125.g002
Partial Inhibition of Breast Cancer by Tamoxifen
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25125estrogen signaling works through binding of estrogen to ERs and
subsequent regulation of estrogen signaling molecules such as PR,
Myc etc. [35,36]. Estrogen receptor and PR regulate an array of
genes involved in cell proliferation and oncogenesis [35]. We
observed E2-mediated increase in ER and PR expression and
inhibition of these receptors by Tam (Figures 3 and 4). Estrogen
also exerts its effect by receptor independent estrogen metabolic
pathways [1,5,37]. During estrogen metabolism, estrogen is
converted to highly toxic metabolite 4-hydroxy estradiol (4-
OHE2) via CYP1B1 enzymatic reaction [38]. 4-hydroxy estradiol
can directly bind to DNA and form DNA adducts [39,40].
Furthermore, 4-OHE2 metabolizes to semiquinone and quinone
[41]. During this conversion of semiquinone to quinone, reactive
oxygen species (ROS) are produced that can damage DNA,
protein and lipids and ultimately leads to oncogenesis [37,40,41].
We have demonstrated that although Tam was able to inhibit ER-
mediated processes, it was unable to reduce oxidative stress
produced by estrogen (Figure 6). Tamoxifen itself has been shown
to induce ROS, and if this is the case one would expect a
cumulative effect of E2 and Tam co-treatment on ROS generation
[24,42]. Antioxidants SOD, GPx and CAT expression levels in
mammary tissues of Tam- and Tam + E2-treated groups provide
an insight to involvement of Tam in regulation of these
antioxidant enzymes (Figure 7). Although, SOD1 protein expres-
sion levels did not change significantly between E2, Tam, and Tam
+ E2 groups, GPx expression was markedly decreased in Tam and
Tam + E2 group compared to E2-treated group (Figure 7). SOD
catalyzes the dismutation of superoxide to generate hydrogen
peroxide, while CAT and GPx are responsible for the decompo-
sition of hydrogen peroxide to oxygen and water. No change in
SOD1 and increase in SOD2 expression (thus, overall increased
SOD levels) without parallel increases in GPx and CAT activity in
Tam- and Tam + E2-treated mammary tissues compared to control
mammary tissues may result in elevated hydrogen peroxide
production. Without sufficient GPx and CAT enzymes available,
it may magnify the burden of oxidative stress in the mammary
tissues. Itmaybe that long-termTamtreatment, perhaps itself alters
Figure 3. Expression of ER-a in mammary tissues. Female ACI rats were treated with E2, Tam or Tam + E2 for 240 days as described in Materials
and Methods section. At the end of the experiment, mammary tissues were collected and used for immunohistochemistry as described in Materials
and Methods section. Formalin-fixed/paraffin-embedded mammary sections were immunostained with ER-a antibody. Nuclear expression of ER-a is
shown in representative sections (arrow). (a) The mammary tissue of a representative control ACI rat; (b) E2-treated mammary tissue; (c) Tam-treated
mammary tissue; and (d) Tam + E2-treated mammary tissue. 1006magnification.
doi:10.1371/journal.pone.0025125.g003
Figure 4. Expression of PR mRNA in mammary tissues. Female
ACI rats were treated with E2, Tam or Tam + E2 for 240 days as
described in Materials and Methods section. At the end of the
experiment, mammary tissues were collected, total RNA isolated and
used for real-time PCR as described in Materials and Methods section.
PR mRNA expression was significantly increased in E2-treated mammary
tissues and it remained unchanged in Tam- and Tam + E2-treated
mammary tissues. mRNA expression data are presented as fold change
versus control mammary tissue. These data are reported as an average
of values obtained for at least 5 different animals 6 SEM. ‘*’ indicates a
p value,0.05 compared to controls.
doi:10.1371/journal.pone.0025125.g004
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generation of oxidative stress.
Estrogen has been shown to induce DNA damage and altered
antioxidant status of the cells has also been shown to be
responsible for increased DNA damage [43]. To further determine
if E2-mediated change in antioxidant status of mammary is also
reflected in DNA damage, we analyzed the 8-OHdG levels as a
marker of oxidative DNA damage in mammary tumors and
mammary tissues. We demonstrated significant increased levels of
8-OHdG in Tam + E2-, E2-treated mammary tissues and in
mammary tumors compared to control mammary tissue
(Figure 10). We also demonstrated that although Tam co-
treatment decreased mammary 8-OHdG levels compared to E2
alone treated mammary tissues, it did not bring them to control
levels. They were still significantly higher compared to Tam-
treated or sham controls. In an earlier study, Tam + E2 treatment
for 7 months has been shown to be involved in reduction of 8-
OHdG levels in rat mammary [44].
Evidence presented in this study further demonstrates that risks
or benefits of Tam treatment depend on the rate of metabolic
Figure 5. Immunohistochemical detection of proliferation marker PCNA in mammary tissues. Female ACI rats were treated with E2, Tam
or Tam + E2 for 240 days as described in Materials and Methods section. At the end of the experiment, mammary tissues were collected in 10%
buffered-formalin. Formalin-fixed/paraffin-embedded mammary tissue sections were immunostained with PCNA antibody. Nuclear expression of
PCNA is shown in representative sections (arrows) at 1006magnification.
doi:10.1371/journal.pone.0025125.g005
Figure 6. 8-iso-prostane F2a (8-isoPGF2a) formation in rat mammary tissues. Female ACI rats were treated with E2, Tam or Tam + E2 for 240
days as described in Materials and Methods section. 8-isoPGF2a levels were measured in mammary tissues from animals in each of these groups. Fold
changes were calculated for E2-treated animals relative to age-matched cholesterol-treated controls. Fold changes were calculated for Tam + E2-
treated animals relative to age-matched Tam-treated controls. The data are reported as an average of fold change values obtained for at least 8
different animals 6 SEM.
doi:10.1371/journal.pone.0025125.g006
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CYP3A4, CYP2D6 and FMO1 are well known enzymes involved
in metabolic conversion and bioactivation or detoxication of Tam
[45,46,47,48,49,50]. CYP3A4 bioactivates Tam to N-desmethyl
Tam and further to a-hydroxylation products (Figure 8A) that have
DNA damaging capabilities [45,47]. Conversely, CYP2D6 and
FMO1 have been shown to be involved in detoxication of Tam and
its metabolites [46,50]. No change in CYP3A4 and CYP2D6
expression and marked decrease in FMO1 protein expression in
Tam + E2-treated mammary tissues indicate a change towards
more bioactivation of Tam that may be responsible for generation
of DNA damaging metabolites (Figure 8B). Furthermore, down-
regulation of FMO1 in E2- and Tam + E2-treated mammary and
no change in the mammary of Tam alone treated group compared
to control mammary, indicates an E2-mediated downregulation of
this enzyme (Figure 8B).
About two-thirds of human breast cancers that respond to ER-
antagonist treatment initially may become somewhat unresponsive
to such treatment eventually [18,51]. The antagonist effects of
Tam in breast tissue are thought to result from its ability of
competing with estradiol to bind to the ERs [12,52]. Inhibition of
expression of ER and PR in mammary tissues after 8 months of
Tam treatment demonstrates continued anti-estrogenic effects of
Tam (Figures 3 and 4). The genes MaoB1 and Cidec are known to
be negatively regulated by estrogen [53,54]. Interestingly,
downregulation of these genes in Tam + E2-treated mammary
in the same manner as in E2-treated mammary suggest that
estrogen remains an important regulator of these genes even after
co-treatment with Tam (Figure 9). Monoamine oxidase B1 is a
ubiquitous enzyme that oxidizes amines including histamine and
xenobiotics to prevent chemical toxicity [54]. High concentrations
of histamine and thus more proliferation in ductal breast cancer
have previously been shown [55]. The increase of histamine
concentration in breast cancer cases could be the outcome of
either more biosynthesis and/or less metabolism of histamine.
Thus, E2-mediated inhibition of MaoB1 in the mammary of Tam
+ E2-treated rats (Figure 9) provides advantage to proliferative
activities in breast as seen in figures 1E and 5. Cidec is a member
of a novel family of cell death-inducing DNA fragmentation factor
(DFF) 45-like effectors [CIDEs] and is involved in induction of
apoptosis [56,57]. Therefore, inhibition of Cidec and thus
apoptosis in the mammary of Tam + E2-treated rats may help
in development of breast cancer (Figures 1F and 9). These data
provide support for the idea that endocrine-targeted therapies can
lead to activation of novel signaling pathways that circumvent the
effects of antiestrogens like Tam. Moreover, estrogen-metabolism
mediated oxidative stress can also augment the nongenomic ER
actions like activation of downstream signaling kinases such as
mitogen-activated protein kinase (MAPK) and AKT, which
orchestrate cell proliferation and survival [58,59]. In addition,
these signaling kinases can, in turn, activate ER itself or its
coactivator proteins, which augment ER-mediated signaling and
promote Tam resistance that ensures the survival of a breast
cancer cell even in the presence of Tam [60]. This nongenomic
ER action has previously been described in many target organs
and tissues including breast [61,62,63].
Overall, our results demonstrate that under conditions of long-
term chronic E2 exposure, Tam does not provide complete
protection against E2-metabolism mediated ROS generation and
DNA damage. Our results are in agreement with the role of
oxidant stress in estrogen-induced carcinogenesis. Although Tam
treatment inhibits estrogen-induced breast tumor development
and increases the latency of tumor development, it does not
completely abrogate estrogen-dependent breast tumor develop-
ment in a rat model of estrogen-induced breast carcinogenesis.
Thus, lack of complete inhibition of E2-induced breast cancer by
Tam may be because of persistent estrogen-induced oxidant stress.
Materials and Methods
Ethics statement
The animals were treated and handled according to the
guidelines of the Columbia University’s Animal Care and Use
Committee. The study was approved by the Institutional Animal
Figure 7. Expression of antioxidant enzymes in mammary
tissues. Female ACI rats were treated with E2, Tam or Tam + E2 for 240
days as described in Materials and Methods section. At the end of the
experiment, mammary tissues were collected, homogenized and used
for western blot analysis. In E2-treated mammary tissue, protein level of
CAT is decreased while SOD2 is increased compared to age-matched
control. In mammary tissues of rats treated with Tam alone or co-
treated with E2, SOD2 is increased, while GPx and CAT are decreased.
SOD1 protein levels remain unchanged in all the treatment groups.
doi:10.1371/journal.pone.0025125.g007
Table 2. Activities of antioxidant enzymes in female ACI rats after 240 days of treatment.
Tissue SOD1 (U/mg protein) SOD2 (U/mg protein) GPx (nmol/min/mg protein) CAT (nmol/min/mg protein)
Control mammary 540624 40614 92698 8 69
E2-treated mammary 16066280* 5686105* 128622 104612
Tam-treated mammary 9836119 35612 39610* 79610
Tam + E2-treated mammary 10346141 70627 5367* 92614
Female ACI rats were treated with E2, Tam or Tam + E2 as described in the Materials and Methods section. The activities of the antioxidant enzymes SOD1, SOD2, GPx
and CAT were measured in mammary tissues from control, E2-, Tam- and Tam + E2-treated rats after 240 days of respective treatment. The data are reported as an
average of values obtained for at least 8 different animals 6 SEM. ‘*’ indicates a p value,0.05 compared to control mammary tissue.
doi:10.1371/journal.pone.0025125.t002
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(approval number AC- AAAA9396).
Treatment of Animals and Histopathological Analysis
Female ACI rats (4 weeks of age; Harlan Sprague Dawley,
Indianapolis, IN) were housed under controlled temperature,
humidity, and lighting conditions. After a one-week acclimatization
period, rats were divided into four groups; i) Control, ii) E2, iii)
Tam, and iv) Tam + E2. Rats were implanted subcutaneously with
3 mg E2 and 40 mg Tam as pellets [7,26]. E2 pellets were prepared
in 17 mg cholesterol as a binder as described previously [1,9,64].
Controland Tamgroupsreceived17 mgcholesterolpellet.Animals
were fed phytoestrogen-free AIN76A diet (Dyets, Bethlehem, PA)
and water was given ad libitum to all the animals. E2, cholesterol and
Tam pellets were prepared using a pellet press as described
previously [65]. Rats were treated with Tam or E2 for 240 days (8
months). Animals were palpated twice weekly to monitor mammary
tumor development. At the end of 240 days of treatment, animals
were anesthetized using isoflurane and euthanized. Mammary,
mammary tumors, ovary, kidney, uterus, lung and liver tissues were
removed and snap-frozen in liquid nitrogen for further studies.
Frozen tissues were stored at 270uC. A portion of all the excised
tissues was stored in 10% buffered formalin for histopathologic
analyses. The formalin-fixed tissue was embedded in paraffin, and
sectionsof4to5 mmthicknesswerecut.Paraffin-embedded sections
of the mammary, liver, uterus, kidney, lung and ovary were stained
with hematoxylin and eosin for histopathologic evaluations. Tumor
incidence and the number of tumor nodules per rat were counted at
the time of dissection.
Immunohistochemical Analysis
Paraffin-embedded blocks were sectioned and mounted on
frost-free slides. Tissue sections of 4–5 mm thickness were
deparaffinized in xylene and rehydrated through a series of
graded alcohols. Tissue sections were washed with 16 PBS and
endogenous peroxidases were blocked with 0.3% hydrogen
peroxide in methanol for 30 min at 25uC. After three 5 min
washes in 16PBS, the sections were incubated for 10 min at 80uC
in 10 mmol/L sodium citrate buffer (pH 6.0) for antigen retrieval.
Tissue sections were then incubated in blocking solution according
to Vectastain Elite ABC kit (Vector laboratories, Burlingame, CA)
for 20 min at 25uC in a humidified chamber. Control (no primary
antibody) and experimental slides were incubated overnight at 4uC
in a humidified chamber in blocking solution with PCNA (1:200,
sc-11407; Santa Cruz Biotechnology, Santa Cruz, CA) or ER-a
antibody (1:200, sc-17774; Santa Cruz Biotechnology, Santa Cruz,
CA). After 5 min wash with 16 PBS, biotinylated secondary
antibody (Vector laboratories) was added and sections were
incubated at 25uC for 2 h and then washed three times with 16
PBS. Tissue sections were then incubated for 30 min with
Vectastain Elite ABC reagent (Vector laboratories). After 16
PBS washing, staining was visualized with DAB substrate kit
(Vector laboratories) according to supplier’s instructions. All
sections were counterstained with Harris hematoxylin, dehydrated
in ethanol, cleared in xylene and mounted with Permount (Fisher
Scientific, Hanover Park, IL). Tissue sections from at least 3
different animals in each group were used for immunostaining.
Images were obtained at 1006 using a Leica DMI 3000B
microscope (Leica Microsystems Inc., Bannockburn, IL).
Analysis of 8-iso-Prostane F2a (8-isoPGF2a) Levels
Total 8-isoPGF2a levels in the mammary and liver tissues of
female ACI rats were quantified using a direct 8-isoPGF2a enzyme
immunoassay kit (Assay Designs, Ann Arbor, MI), according to the
suppliers instructions, as described previously [1,7, {Singh, 2010
#1122}]. Briefly, rat mammary and liver tissues (50–100 mg)
Figure 8. Tamoxifen metabolizing enzymes in mammary tissues. (A) Primary enzymes involved in metabolism of Tam in mammary tissues.
Regular arrows indicate the detoxication steps in the pathway, while bold arrows indicate CYP3A4-mediated bioactivation processes. (B) Female ACI
rats were treated with E2, Tam or Tam + E2 for 240 days as described in Materials and Methods section. At the end of the experiment, mammary
tissues were collected, homogenized and used for western blot analysis. CYP3A4 and CYP2D6 protein levels remain unchanged in all the treatment
groups but the FMO1 protein expression is decreased in E2- and Tam + E2-treated mammary tissues.
doi:10.1371/journal.pone.0025125.g008
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butylated hydroxytolulene. Homogenization was carried out in the
TissueLyser (Qiagen, Valencia, CA) at 29 cycles per second for
4 min at 1 min intervals. Protein concentrations from the
homogenates were determined using the Pierce BCA protein
assay kit (Pierce, Rockford, IL). For determination of 8-isoPGF2a
levels, 100 ml of the homogenate from each tissue was hydrolyzed
by incubation with 25 ml of 10 N NaOH at 45uC for 2 h. The
reaction mixture was cooled on ice for 5 min, neutralized with
25 ml of 12 N HCl and centrifuged for 5 min at 4uC. Fifty
microliter of the hydrolyzed/neutralized supernatant sample was
then used in the 96-well format 8-isoPGF2a assay. Samples were
incubated with the 8-isoPGF2a antibody for 18 h at 4uC. The
contents of the wells were emptied after incubation and washed
with wash buffer. After complete removal of wash buffer from the
wells, the color was developed by incubation with 200 mlo fp -
nitrophenyl phosphate for 45 min, at room temperature. The
reaction was stopped by the addition of 50 ml of stop solution and
the plate was read at 405 nm. Standards were run on each plate
and standard curve was generated by measuring the optical
density of 160–100,000 pg/ml of 8-isoPGF2a standards that were
processed simultaneously with the unknown samples. Data were
expressed as mean 8-isoPGF2a pg/mg protein 6 SEM. Fold
changes were calculated by comparing 8-isoPGF2a levels detected
in the mammary or liver tissue of treated animals to levels in the
respective tissue of age-matched control animals.
Analysis of SOD, GPx and CAT Activity
Total SOD, GPx and CAT activities were quantified using
commercially available kits from Cayman Chemical Company
(Ann Arbor, MI) and as reported recently [7,9]. Briefly, the total
SOD activity was quantified using a tetrazolium salt for detection
of superoxide radicals, generated by xanthine oxidase and
hypoxanthine. Approximately 50 mg of mammary or liver tissue
was homogenized in 50 mM phosphate buffer containing 1 mM
EDTA, 210 mM mannitol and 70 mM sucrose. After homogeni-
zation, homogenates were centrifuged at 15006g for 5 min at
4uC. The supernatant was removed and the protein concentration
Figure 9. Expression of estrogen regulated genes MaoB1 and
Cidec in mammary tissues. Female ACI rats were treated with E2,
Tam or Tam + E2 for 240 days as described in Materials and Methods
section. mRNA expression levels of MaoB1 and Cidec gene in E2-, Tam-
and Tam + E2-treated mammary tissues using quantitative real-time
PCR are presented as fold change versus control mammary tissues.
Expression of each gene was normalized using cyclophilin as internal
control. These data are reported as an average of values obtained for at
least 5 different animals 6 SEM. ‘*’ indicates a p value,0.05 compared
to controls.
doi:10.1371/journal.pone.0025125.g009
Figure 10. 8-hydroxydeoxyguanosine (8-OHdG) levels in mammary tissues and mammary tumors. Female ACI rats were treated with E2,
Tam and Tam + E2 for 240 days as described in Materials and Methods section. 8-OHdG levels were measured in mammary tumors and mammary
tissues from animals in each of these groups. 8-OHdG levels are significantly increased in E2-treated mammary tissues, mammary tumor tissues and
Tam + E2-treated mammary tissues. 8-OHdG levels remain unchanged in Tam-treated mammary tissues compared to control. These data are reported
as an average of values obtained for at least 8 different animals 6 SEM. ‘*’ indicates a p value,0.05 compared to controls.
doi:10.1371/journal.pone.0025125.g010
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IL). SOD2 activity was also quantified simultaneously with the
total SOD activity using 3 mM potassium cyanide in the assay that
inhibits both SOD1 and SOD3 [66]. Standards were run on each
plate along with the unknown samples for generation of standard
curve. The absorbance of the sample and standards were
measured at 450 nm, using a plate reader (Versamax Microplate
Reader, Molecular Devices, Sunnyvale, CA). SOD3 activity was
quantified using an in-gel activity staining assay as described
previously (24). The same protein samples that were used in total
SOD activity assay were used for SOD3 in-gel activity assay. The
protein samples were separated by polyacrylamide gel electropho-
resis. The gel was then soaked in a solution containing nitroblue
tetrazolium, riboflavin, and N,N,N9,N9-tetramethylethylenedia-
mine. The gel was then illuminated at 560 nm for 15 min. During
light exposure, the area where SOD3 activity was located showed
an achromatic band on the gel. After 15 min, the gel image was
captured with Alpha Innotech FluorChem HD2 (Alpha Innotech,
San Leandro, CA) gel documentation system and quantified using
AlphaEase FC StandAlone software (version 6.0.0.14; Alpha
Innotech). The activity of SOD3 was determined based on the
image intensities produced by the standard of bovine erythrocyte
SOD3 (Sigma, St. Louis, MO) in the activity gels. SOD1 activity
was obtained by subtracting SOD2 and SOD3 activities from total
SOD activity of that particular sample. SOD activities were
reported as units/mg protein.
The GPx assay kit measures GPx activity by way of a coupled
reaction with glutathione reductase. This assay is based on the
production of oxidized glutathione during reduction of hydroper-
oxide by GPx and then recycling to its reduced state by
glutathione reductase and NADPH. The oxidation of NADPH
to NADP
+ causes a decrease in the absorbance at 340 nm. The
rate of decrease in the absorbance of the samples at 340 nm is
directly proportional to the GPx activity in the sample. At the time
of analysis, approximately 50 mg of mammary or liver tissue was
homogenized in 50 mM phosphate buffer containing 1 mM
EDTA, 210 mM mannitol and 70 mM sucrose. After homogeni-
zation, homogenates were centrifuged at 10,0006g for 15 min at
4uC. Seven time points with a gap of 1 min were obtained in order
to accurately assess the decrease in absorbance at 340 nm. GPx
activity was reported as nmol/min/mg protein.
The determination of CAT activity is based on the reaction of
the CAT enzyme with methanol, in the presence of an optimal
concentration of H2O2. The formaldehyde produced is measured
spectrophotometrically at 540 nm using 4-amino-3-hydrazino-5-
mercapto-1, 2, 4-triazole (Purpald) as the chromogen. Purpald
specifically forms a bicyclic heterocycle with aldehydes, which
changes from colorless to purple following oxidation. At the time
of analysis, approximately 50 mg of mammary or liver tissue was
homogenized in 50 mM phosphate buffer containing 1 mM
EDTA, 210 mM mannitol and 70 mM sucrose. After homogeni-
zation, homogenates were centrifuged at 10,0006g for 15 min at
4uC. Standards were run simultaneously on each plate. CAT
activity was reported as nmol/min/mg protein. Fold changes in
SOD, GPx and CAT activity were calculated by comparing
enzyme activity in the mammary or liver tissue of treated groups to
the activity measured in the respective tissue of age-matched
respective controls.
Reverse Transcription and Real-time PCR
Total RNA was isolated from ACI rat mammary and mammary
tumors from 8 month treatment groups using RNeasy lipid tissue
kit (Qiagen, Valencia, CA) and QIAcube automated machine
according to the supplier’s protocols. Five microgram total RNA
was reverse transcribed using the superscript II reverse transcrip-
tion system and an oligo-dT16–18 primer (Invitrogen, Carlsbad,
CA). Real-time PCR was performed using rat specific PR,
monoamine oxygenase B1 (MaoB1) and cell death inducing DFF45 like
effector C (Cidec) QuantiTect primers and QuantiFast SYBR green
master mix (Qiagen, Valencia, CA) in duplicate 25 ml reactions by
using iCycler iQ5 system (BioRad Laboratories, Hercules, CA).
Data were analyzed from at least 5 different animals from each
group using BioRad iQ5 optical system software version 2.0. The
expression of cyclophilin, a housekeeping gene, was used for
quantification and standardization purposes whose expression has
previously been shown not to be altered by estrogen treatment
[67]. The expression of gene of interest relative to cyclophilin was
determined by dividing the number of cDNA molecules for the
gene of interest by the number of cyclophilin cDNA molecules.
Standards were created for each gene and a standard curve was
run on each plate to allow for accurate quantification of cDNA, as
reported previously [67].
Western Blot Analysis
Approximately 50 mg of ACI rat mammary tumor and
mammary tissues were homogenized in a tissue protein extraction
buffer (T-PER, Thermo Scientific, IL) using a PRO 200 rotor
stator homogenizer (PRO Scientific, CT). After homogenization,
samples were centrifuged at 10,0006g and the clear supernatant
was saved. The Pierce BCA Protein Assay kit was used to
determine the protein concentration of each sample (Pierce,
Rockford, IL). Sixty micrograms total protein was size fractionated
on a 12% SDS-polyacrylamide gel, and transferred onto a PVDF
membrane under standard conditions. Membranes were blocked
in 5% dry non-fat milk/PBS/0.05% Tween-20 for 2 h. Cyto-
chrome P450 3A4 (CYP3A4) (BD Biosciences, San Jose, CA),
CYP2D6, FMO1, SOD1, SOD2, GPx-1/2 and CAT primary
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were
diluted in PBS/0.05% Tween-20 and used individually for
immunodetection. After overnight incubation at room tempera-
ture with the primary antibody, membranes were washed four
times with 8 min per wash using PBS/0.05% Tween-20.
Membranes were then incubated with horse radish peroxidase-
conjugated respective secondary antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA) diluted in PBS/0.05% Tween-20. After
incubation for 2 h at room temperature, the membranes were
washed again as described above. Chemiluminescent detection
was performed using the BM Chemiluminescence Detection kit
(Roche, Indianapolis, IN) and Alpha Innotech FluorChem HD2
(Alpha Innotech, San Leandro, CA) gel documentation system.
Membranes probed for desired protein were stripped and washed
in PBS/0.05% Tween-20 and reprobed with a-tubulin rat
monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) using the method described above. Protein samples from at
least 3 different animals in each group were used for immuno-
blotting. Intensities of the bands were quantified and normalized
using AlphaEase FC StandAlone software (version 6.0.0.14; Alpha
Innotech).
8-hydroxydeoxyguanosine (8-OHdG) Analysis
8-hydroxydeoxyguanosine, a ubiquitous marker of oxidative
DNA damage was estimated in mammary tumors and in
mammary tissues of rats treated with E2 in the presence or
absence of Tam as well as in age-matched controls. DNA was
isolated using DNeasy blood & tissue kit (Qiagen, Valencia, CA)
according to the supplier’s protocols with some modifications.
Diethylenetriamine pentaacetic acid (0.1 mM) and ascorbic acid
(2 mM) were used throughout the DNA isolation process to avoid
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degrade RNA as per supplier’s protocol. The RNA-free DNA thus
obtained was used to estimate 8-OHdG levels using Oxiselect
oxidative DNA damage ELISA kit (Cell Biolabs, San Diego, CA)
according to supplier’s protocols with some modifications as
described earlier [68]. Briefly, 20 mg DNA was digested with 10 U
DNase 1 (Qiagen, Valencia, CA) at 37uC for 30 min in presence
of 100 mM MgCl2 and 1 M Tris-HCl (pH 7.4). After DNA
digestion with DNase 1, pH was adjusted to 5.2 with 3 M sodium
acetate (pH 5.2) and DNA reaction mixture was subjected to 1 ml
of nuclease P1 (1 U/ml) digestion for 1.5 h at 37uC. After 1.5 h
incubation, 1 M Tris-HCl (pH 8.0) was used to bring the pH back
to 7.4 followed by 1 ml of alkaline phosphatase (1 U/ml stock)
treatment for 1 h. The reaction mixture was then subjected to 1 ml
of each phosphodiesterase I (0.01 U/ml) and phosphodiesterase II
(0.01 U/ml) digestion for 30 min at 37uC. The reaction mixture
was centrifuged for 5 min at 60006g and the supernatant was
used for 8-OHdG ELISA assay.
Statistical Analyses
Statistical analysis was performed by using Sigma Plot 11.0
(Systat Software, San Jose, CA). Fisher’s exact test was used to
compare tumor incidence between two treatment groups, or
between a treatment group and a specific control group. 8-iso-
Prostane F2a, 8-OHdG, SOD, CAT and GPx assays were all done
using at least 8 samples from 8 different animals in each treatment
group. The unpaired t-test analysis was used to calculate p values
for comparisons between the treated animals and their respective
age-matched controls. A p value ,0.05 was considered significant.
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